The 9th iteration of the 'Impact of Biosimilar Competition in Europe' report describes the effects on price, volume, and market share following the arrival of biosimilar competition in Europe. The report consists of observations on competitive markets, and a set of Key Performance Indicators (KPIs) to monitor the impact of biosimilars in 23 European markets. The report has been a long-standing source of information on the status of the biosimilars market.

In 2023 IQVIA's observations remain focused on the European Commission's priority areas and the benefits of biosimilar competition, but have an emphasis on the pipeline and competitor entry which is under increased scrutiny given the potential from future loss of exclusivity (LoE) events. In 2023, the observations on the impact of biosimilar competition are as follows:

• Access: Access to current biologics signals access challenges as disparity grows
• Savings: Savings growth has fallen from list prices due to the LoE opportunity
• Pipeline: Guaranteed savings do not exist for all classes as the pipeline shows gaps
• Policy: Policy changes take time to impact, and are part of a multifactorial environment
• Future: A new era of molecules losing exclusivity show changing dynamics